Ultragenyx Pharmaceutical (RARE) Cash from Operations Growth (1y) (2014 - 2026)
Ultragenyx Pharmaceutical (RARE) Cash from Operations Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 60.84% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 85.14% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.72% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 74.39% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn | -18.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.67% |
| Dec 31, 2025 | -25.86% |
| Sep 30, 2025 | -36.46% |
| Jun 30, 2025 | -41.30% |
| Mar 31, 2025 | 12.96% |
| Dec 31, 2024 | 5.69% |
| Sep 30, 2024 | 43.16% |
| Jun 30, 2024 | 33.74% |
| Mar 31, 2024 | -21.59% |
| Dec 31, 2023 | 6.91% |
| Sep 30, 2023 | -23.63% |
| Jun 30, 2023 | -50.36% |
| Mar 31, 2023 | -33.48% |
| Dec 31, 2022 | -66.24% |
| Sep 30, 2022 | -59.84% |
| Jun 30, 2022 | -18.21% |
| Mar 31, 2022 | 26.25% |
| Dec 31, 2021 | 12.98% |
| Sep 30, 2021 | 3.74% |
| Jun 30, 2021 | -174.82% |